여성건강진단 시장 : 유형별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global women's health diagnostics market size reached USD 31.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 54.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.4% during 2025-2033. The market is propelled by the rising number of individuals diagnosed with chronic and lifestyle-related diseases, significant technological developments in diagnostic services, increasing awareness about women's health through numerous campaigns and initiatives by the governments and public organizations, increasing acceptance rate of point-of-care diagnostics, and rapid growth in telemedicine and remote diagnostics industry.

Women's health diagnostics help diagnose various biological and psychosocial conditions of female patients. They assist in addressing sexual and vaginal issues and pregnancy complications and managing threatening diseases, such as osteoporosis, menopause, and certain cancers like breast and cervical. They rely on a series of advanced laboratory tests, tools, and procedures, which include biopsy, ultrasound, chemotherapy, and magnetic resonance imaging (MRI). Several healthcare diagnostics centers are currently offering an expansive range of laboratory testing solutions to enhance the diagnosis and management of rare diseases and conditions that affect women.

Women's Health Diagnostics Market Trends:

The rising prevalence of health issues that impact the overall well-being of women represents one of the major factors influencing the market positively. Moreover, the growing health consciousness, along with the increasing awareness about the benefits of early diagnosis, is catalyzing the demand for point-of-care (POC) women's health diagnostics across the globe. Apart from this, the rising rate of infertility on account of stressful lifestyles and the growing consumption of alcohol and drugs is driving the need for women's health diagnostics to address pregnancy complications and ensure a healthier life. Furthermore, as menopause can increase the risk of developing certain medical conditions, including cardiovascular diseases and urinary incontinence, a significant rise in the female population which is over 50 years is contributing to the market growth. Besides this, several research studies have concluded that women are more likely to experience psychiatric disorders, such as depression and anxiety, during hormonal changes. This, in confluence with several initiatives undertaken by health agencies of numerous countries to improve mental health of women, is propelling the market growth across the globe.

Key Market Segmentation:

Breakup by Type:

• Diagnostic Devices
• Biopsy Device
• Imaging and Monitoring Devices
• Accessories and Consumables
• Diagnostic Tests
• Breast Cancer Testing
• PAP Smear and HPV Test
• Pregnancy Testing and Ovulation Testing
• Others

Breakup by Application:

• Breast Cancer
• Infectious Disease Testing
• Osteoporosis Testing
• Pregnancy and Fertility Testing
• Sexually Transmitted Disease Testing
• Others

Breakup by End User:

• Hospital and Diagnostics Centers
• Home Care

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Cardinal Health Inc., Cook Group Incorporated, F. Hoffmann-La Roche AG, General Electric Company, Hologic Inc., Koninklijke Philips N.V., Perkinelmer Inc., Quest Diagnostics Inc., Siemens AG and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global women's health diagnostics market in 2024?
• 2.What is the expected growth rate of the global women's health diagnostics market during 2025-2033?
• 3.What are the key factors driving the global women's health diagnostics market?
• 4.What has been the impact of COVID-19 on the global women's health diagnostics market?
• 5.What is the breakup of the global women's health diagnostics market based on the type?
• 6.What is the breakup of the global women's health diagnostics market based on the application?
• 7.What is the breakup of the global women's health diagnostics market based on the end user?
• 8.What are the key regions in the global women's health diagnostics market?
• 9.Who are the key players/companies in the global women's health diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Women's Health Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Diagnostic Devices
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Biopsy Device
    • 6.1.2.2 Imaging and Monitoring Devices
    • 6.1.2.3 Accessories and Consumables
  • 6.1.3 Market Forecast
• 6.2 Diagnostic Tests
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Breast Cancer Testing
    • 6.2.2.2 PAP Smear and HPV Test
    • 6.2.2.3 Pregnancy Testing and Ovulation Testing
    • 6.2.2.4 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Application

• 7.1 Breast Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Infectious Disease Testing
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Osteoporosis Testing
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pregnancy and Fertility Testing
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Sexually Transmitted Disease Testing
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospital and Diagnostics Centers
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Home Care
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Becton Dickinson and Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 bioMerieux SA
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Cardinal Health Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Cook Group Incorporated
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 F. Hoffmann-La Roche AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 General Electric Company
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Hologic Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Koninklijke Philips N.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Perkinelmer Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Quest Diagnostics Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Siemens AG
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Thermo Fisher Scientific Inc.
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis